Compare LEE & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEE | LIXT |
|---|---|---|
| Founded | 1890 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.3M | 25.4M |
| IPO Year | N/A | N/A |
| Metric | LEE | LIXT |
|---|---|---|
| Price | $5.24 | $2.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 88.4K | 79.7K |
| Earning Date | 02-05-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $562,341,000.00 | N/A |
| Revenue This Year | $5.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.34 | $0.64 |
| 52 Week High | $15.15 | $6.26 |
| Indicator | LEE | LIXT |
|---|---|---|
| Relative Strength Index (RSI) | 66.83 | 29.61 |
| Support Level | $4.60 | $3.26 |
| Resistance Level | $5.33 | $3.66 |
| Average True Range (ATR) | 0.43 | 0.29 |
| MACD | 0.07 | -0.07 |
| Stochastic Oscillator | 78.74 | 1.30 |
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.